IP Library › Granted Patent US 7,189,735
Granted Patent B2
US 7,189,735 · App. 10/374,644 · Granted Mar 13, 2007

Use of CCI-779 as an antineoplastic agent

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,189,735
App. No.
10/374,644
Granted
Mar 13, 2007
Kind
B2
Abstract

This invention provides the use of CCI-779 in the treatment of neoplasms.

Claims (8)

1. A method of treating a refractory neoplasm in a mammal in need thereof, which comprises administering to said mammal an effective amount of CCI-779, wherein said mammal has been previously treated with standard chemotherapy and wherein said refractory neoplasm has progressed following treatment with said standard chemotherapy, wherein said refractory neoplasm is selected from the group consisting of soft tissue carcinoma, breast cancer, neuoroendocrine tumor of the lung, cervical cancer, uterine cancer, head and neck cancer, and non-small cell lung cancer.

2. The method according to claim 1 , wherein the refractory neoplasm is soft tissue carcinoma.

3. A method of treating refractory breast cancer in a mammal in need thereof, which comprises providing to said mammal an effective amount of CCI-779, wherein said mammal has been previously treated with standard chemotherapy and wherein said refractory breast cancer has progressed following treatment with said standard chemotherapy.

4. The method according to claim 1 , wherein the refractory neoplasm is a neuroendocrine tumor of the lung.

5. The method according to claim 1 , wherein the refractory neoplasm is cervical cancer.

6. The method according to claim 1 , wherein the refractory neoplasm is uterine cancer.

7. The method according to claim 1 , wherein the refractory neoplasm is a head and neck cancer.

8. The method according to claim 1 , wherein the refractory neoplasm is non-small cell lung cancer.